<DOC>
	<DOCNO>NCT02070523</DOCNO>
	<brief_summary>To determine , compare Daunorubicin ( DNR ) , whether Pegylated liposomal doxorubicin ( PLD ) induce high complete remission ( CR ) rate , untreated primary ALL adult patient VDCLD regimen induction therapy . Second , determine , compare DNR , whether chemotherapy contain PLD high response rate great safety adult ALL</brief_summary>
	<brief_title>Pegylated Liposomal Doxorubicin Versus Daunorubicin Treat Acute Lymphoblastic Leukemia :</brief_title>
	<detailed_description>This prospective , multicenter , open , non-intervention clinical study , estimate enrollment 200 newly diagnose adult ALL patient . After first course treatment administer PLD-contained DNR-contained VDCLD regimen , CR rate change leukemia stem cell bone marrow , evaluate ; safety chemotherapy also evaluate . Study Patients : Patients include study untreated ALL previously , line inclusion criterion exclusion criterion . Dosage Administration : PLD-contained VDCLD regimen：PLD 36 mg/m2 ivdrip 60 minute ( d1、15 ) , VCR 1.4mg/m iv ( d1，8，15，22 ) , CTX 800 mg/m2 ivdrip ( d1 ) , L-asp 6000u/m2 ivdrip ( d19～28 ) , Dex10mg ivdrip ( d1～28 ) . DNR-contained VDCLD regimen：DNR 45 mg/m2 ivdrip 60 minute ( d1～3 ) , VCR 1.4mg/m2 iv ( d1，d8，d15，d22 ) , CTX 800 mg/m2 ivdrip ( d1 ) , L-asp 6000u/m2 ivdrip ( d19～28 ) , Dex10mg ivdrip ( d1～28 ) . Endpoints : Primary endpoint : The primary endpoint study complete remission ( CR ) rate first course regimen . The proportion patient achieve CR evaluate , first course induction chemotherapy administer PLD-contained DNR-contained VDCLD regimen Secondary endpoint : The change leukemia stem cell bone marrow , evaluate administer PLD-contained DNR-contained VDCLD regimen . Safety Assessment : In order adjust treatment strategy ensure patient ' safety effectively , routine blood test , transaminase , creatinine monitor time period , lung CT ECG perform base clinical need . Possible adverse reaction tolerability treatment , gastrointestinal reaction , cardiac function , well discontinuation ratio due side effect tolerability PLD , record . Statistical Analysis : All calculation perform SPSS statistical software . The continuous variable perform T test ; categorical variable perform withχ2 test . After acceptance various observation record sheet , data unify process .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Eligible men woman age 14，but less 60 year ; Eastern Cooperative Oncology Group performance status 0 to2 ; Diagnosed ALL ( WHO classification , primitive cell ≥ 20 % ) ; Previous untreated ALL patient receive chemotherapy ( exclude dexamethasone , prednisone , hydroxyurea ) . History receive blood transfusion , hematopoietic growth factor , vitamin , palliative measure leukocyte removal , dexamethasone , prednisone , hydroxyurea ( 0.53g daily , three day ) allow ; The level LSCs bone marrow measure flow cytometry treatment ; Subjects must able provide write informed consent . Mixed type AL patient ; Clinically significant active infection ; Nursing ( breastfeed ) intend nurse study； Pregnancy , intend become pregnant study ; Patients cardiac dysfunction currently ( especially congestive heart failure ) history congestive heart failure ; Patients severe liver failure ( ALT ≥ 5 time upper limit normal ( ULN ) , total bilirubin ≥ 3mg/dL ) Patients renal insufficiency , creatinine clearance &lt; 30ml/min , creatinine clearance rate calculate follow : Men : Ccr ( ml / min ) = ( 140 age ) × weight ( kg ) / [ 0.8136 × serum creatinine ( μmol / L ) ] female : Ccr ( ml / min ) = ( 140 age ) × weight ( kg ) × 0.85 / [ 0.8136 × serum creatinine ( μmol / L ) ] ; Patients participate trial drug 30 day 90 day begin study ,</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>